JP Morgan Chase’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-601,363
| Closed | -$6M | – | 7579 |
|
|
2025
Q2 | $6M | Sell |
601,363
-1,381,300
| -70% | -$11.1M | ﹤0.01% | 2988 |
|
|
2025
Q1 | $11.8M | Sell |
1,982,663
-86,133
| -4% | -$632K | ﹤0.01% | 2386 |
|
|
2024
Q4 | $15.9M | Buy |
2,068,796
+1,601,477
| +343% | +$13.8M | ﹤0.01% | 2249 |
|
|
2024
Q3 | $4.77M | Buy |
467,319
+5,368
| +1% | +$81.9K | ﹤0.01% | 3254 |
|
|
2024
Q2 | $6.86M | Buy |
461,951
+444,193
| +2,501% | +$6.36M | ﹤0.01% | 2785 |
|
|
2024
Q1 | $242K | Sell |
17,758
-5,494
| -24% | -$59.9K | ﹤0.01% | 5246 |
|
|
2023
Q4 | $255K | Sell |
23,252
-449
| -2% | -$4.45K | ﹤0.01% | 5236 |
|
|
2023
Q3 | $260K | Buy |
23,701
+3,253
| +16% | +$41.6K | ﹤0.01% | 4898 |
|
|
2023
Q2 | $271K | Sell |
20,448
-505,709
| -96% | -$7.21M | ﹤0.01% | 4890 |
|
|
2023
Q1 | $7.16M | Sell |
526,157
-57,801
| -10% | -$1.04M | ﹤0.01% | 2550 |
|
|
2022
Q4 | $11.4M | Buy |
583,958
+41,053
| +8% | +$802K | ﹤0.01% | 2134 |
|
|
2022
Q3 | $10.3M | Sell |
542,905
-16,394
| -3% | -$378K | ﹤0.01% | 2127 |
|
|
2022
Q2 | $11.5M | Buy |
559,299
+332,625
| +147% | +$7.89M | ﹤0.01% | 2037 |
|
|
2022
Q1 | $7.29M | Buy |
226,674
+167,992
| +286% | +$6.1M | ﹤0.01% | 2671 |
|
|
2021
Q4 | $2.73M | Buy |
58,682
+44,131
| +303% | +$1.47M | ﹤0.01% | 3596 |
|
|
2021
Q3 | $393K | Buy |
14,551
+2,567
| +21% | +$67.1K | ﹤0.01% | 4862 |
|
|
2021
Q2 | $307K | Buy |
11,984
+2,058
| +21% | +$49K | ﹤0.01% | 5001 |
|
|
2021
Q1 | $339K | Buy |
9,926
+4,890
| +97% | +$177K | ﹤0.01% | 4900 |
|
|
2020
Q4 | $170K | Buy |
5,036
+1,052
| +26% | +$27.9K | ﹤0.01% | 4863 |
|
|
2020
Q3 | $96K | Buy |
+3,984
| New | +$107K | ﹤0.01% | 4710 |
|
Other funds holding ITOS
JP Morgan Chase's ITOS Position: Q3 2025 in Review
JP Morgan Chase sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 601,363 shares — an estimated $6M sold.
JP Morgan Chase first reported a position in ITOS in Q3 2020 and held it in 20 quarters. The position peaked at $15.9M in Q4 2024. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- JP Morgan Chase reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- JP Morgan Chase sold 601,363 iTeos Therapeutics shares in Q3 2025, an estimated $6M.
- JP Morgan Chase first reported a position in iTeos Therapeutics in Q3 2020 and held it in 20 quarters.
- JP Morgan Chase's iTeos Therapeutics position peaked at $15.9M in Q4 2024.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.